Term Name: trametinib dimethyl sulfoxide
Synonyms: GSK1120212, GSK1120212B, JTP 74057, Mekinist, N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide--(methylsulfinyl)methane (1/1), Trametinib DMSO
Definition: An addition compound obtained by combining equimolar amounts of trametinib and dimethyl sulfoxide. Used for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment.
Ontology: ChEBI [CHEBI:75991]  ( EBI )

Relationships
is a type of: addition compound
has_part: dimethyl sulfoxide trametinib
has_role: antineoplastic agent EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor